<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02532413</url>
  </required_header>
  <id_info>
    <org_study_id>81461130019C5</org_study_id>
    <nct_id>NCT02532413</nct_id>
  </id_info>
  <brief_title>Antiviral Efficacy of the Combination Treatment With Poly IC and Entecavir for Chronic Hepatitis B</brief_title>
  <official_title>Comparison of Antiviral Efficacy of Entecavir Monotherapy and Combination Treatment With Poly IC for Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuhan Union Hospital, China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate antiviral efficacy of the combination treatment
      with Poly IC and Entecavir and compare with the efficacy of Entecavir mono-therapy for
      chronic hepatitis B.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the patients with chronic HBV infection will be divided into two groups: HBeAg
      (+) and HBeAg (-) group. Each group will be divided into two subgroups, which are treated
      with combination treatment of Entecavir and Poly IC and Entecavir monotherapy respectively.
      All the patients will be followed up for one year. From this study, the investigators want to
      study if Poly IC can enhance antiviral efficacy of Entecavir for chronic hepatitis B.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with HBsAg serological response</measure>
    <time_frame>at week 48 of treatment</time_frame>
    <description>The proportion of patients who achieve HBsAg serological response as assessed by the rate of HBsAg seroconversion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in serum HBV DNA levels</measure>
    <time_frame>at week 4，12，24，36，48，72，96 of treatment</time_frame>
    <description>Changes in serum HBV DNA levels during 48 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical Response （the serum levels of ALT and AST） Biochemical Response</measure>
    <time_frame>at week 1，2，4，8，12，16，20，24，36，48，72，96 of treatment</time_frame>
    <description>Biochemical response as assessed by the serum levels of ALT, AST, TB, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with HBeAg serological response</measure>
    <time_frame>at week 48 of treatment</time_frame>
    <description>The proportion of patients who achieve HBeAg serological response as assessed by the rate of HBeAg loss or HBeAg seroconversion.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>HBeAg(+):Poly IC+Entecavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>45 subjects(HBeAg-positive chronic hepatitis B). Combination therapy will last 24 weeks from 0 week.
Drug: Entecavir 0.5mg, P.O.,qd, duration:48 weeks. Drug: PolyIC 2mg,im,qod,duration:from 0 week to 24th week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HBeAg(+):Entecavir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>45 subjects(HBeAg-positive chronic hepatitis B). Drug: Entecavir 0.5mg, P.O.,qd, duration:48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HBeAg(-):Poly IC+Entecavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>45 subjects(HBeAg-negative chronic hepatitis B). Combination treatment will last 24 weeks from 0 week.
Drug: Enticavir 0.5mg, P.O.,qd, duration:48 weeks. Drug: PolyIC 2mg,im,qod,duration:from 0 week to 24th week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HBeAg(-):Entecavir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>45 subjects(HBeAg-negative chronic hepatitis B). Drug: Entecavir 0.5mg, P.O.,qd, duration:48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Poly IC</intervention_name>
    <description>Poly IC can induce innate immune responses.It may enhance the antiviral efficacy of Entecavir.</description>
    <arm_group_label>HBeAg(+):Poly IC+Entecavir</arm_group_label>
    <arm_group_label>HBeAg(-):Poly IC+Entecavir</arm_group_label>
    <other_name>Polyinosinic-polycytidylic acid injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>Entecavir can inhibit the replication of HBV.</description>
    <arm_group_label>HBeAg(+):Poly IC+Entecavir</arm_group_label>
    <arm_group_label>HBeAg(+):Entecavir</arm_group_label>
    <arm_group_label>HBeAg(-):Poly IC+Entecavir</arm_group_label>
    <arm_group_label>HBeAg(-):Entecavir</arm_group_label>
    <other_name>Leiyide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HBsAg positive for more than 6 months.

          -  Having been treated wit Entecavir and the level of HBV DNA is under 1000 copies/ml.

          -  ALT ≤10×ULN， TB ＜2ULN .

        Exclusion Criteria:

          -  Previous antiviral treatment for HBV.

          -  Co infection of HIV, HCV, HEV, HAV, or HAV.

          -  Evidence of hepatic carcinoma.

          -  Evidence of autoimmune disease.

          -  Evidence of thyroid disease.

          -  History of mental sickness.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liang D Yang, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Huanzhong University of Science and Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xin Zheng, M.D.</last_name>
    <phone>(00)-86-02785726732</phone>
    <email>zheng2015uh@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jin Tian, M.S.</last_name>
    <phone>(00)-86-02785726132</phone>
    <email>tjxhtj@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Infectious Disease of Wu Han Union Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Zheng, M.D.</last_name>
      <phone>(00)-86-02785726732</phone>
      <email>zheng2015uh@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Jin Tian, M.S.</last_name>
      <phone>(00)-86-02785726132</phone>
      <email>tjxhtj@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2015</study_first_submitted>
  <study_first_submitted_qc>August 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2015</study_first_posted>
  <last_update_submitted>August 22, 2015</last_update_submitted>
  <last_update_submitted_qc>August 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wuhan Union Hospital, China</investigator_affiliation>
    <investigator_full_name>Xin Zheng</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
    <mesh_term>Entecavir</mesh_term>
    <mesh_term>Poly I-C</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

